Couzin-Frankel J. Obesity meets its match: blockbuster weight loss drugs show promise for a wider range of health benefits. Science. 2023;382:1227.

Article  Google Scholar 

Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414–25.

Article  CAS  PubMed  Google Scholar 

Liu BY, Rome BN. State Coverage and Reimbursement of Antiobesity Medications in Medicaid. JAMA. 2024;331:1230–1.

Article  PubMed  PubMed Central  Google Scholar 

Cawley J, Biener A, Meyerhoefer C, Ding Y, Zvenyach T, Smolarz BG, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm. 2021;27:354–66.

PubMed  Google Scholar 

Trogdon JG, Finkelstein EA, Hylands T, Dellea PS, Kamal‐Bahl SJ. Indirect costs of obesity: a review of the current literature. Obes Rev. 2008;9:489–500.

Article  CAS  PubMed  Google Scholar 

Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev. 2011;12:131–41.

Article  CAS  PubMed  Google Scholar 

Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19:1242–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23:754–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46:998–1004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peck E. How weight loss drugs like Ozempic could radically reshape the food business. Axios, Oct, 2023. Accessed May 3, 2024. https://www.axios.com/2023/10/06/ozempic-weight-loss-drugs-food-business.

Bettadapura S, Dowling K, Jablon K, Al-Humadi AW & le Roux CW. Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities. Int J Obes. 2024 (Mar 7);1–9.

U.S. Bureau of Labor Statistics. Consumer Expenditure Surveys. Undated. Accessed April 20, 2024. https://www.bls.gov/cex/.

Green L, Taddei-Allen P. Shifting paradigms: reframing coverage of antiobesity medications for plan sponsors. J Manag Care Spec Pharm. 2023;29:564–8.

PubMed  Google Scholar 

Nguyen T, Wong E, Cope R. Evaluating the efficacy and pharmacoeconomics of semaglutide and tirzepatide in the setting of obesity. Am J Ther. 2023;30:e347–52.

Article  PubMed  Google Scholar 

Levi J, Wang J, Venter F, Hill A. Estimated minimum prices and lowest available national prices for antiobesity medications: improving affordability and access to treatment. Obes (Silver Spring). 2023;31:1270–9.

Article  Google Scholar 

U.S. Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers: Food in U.S. City Average. Accessed May, 2024. https://fred.stlouisfed.org/series/CPIUFDNS.

Guzman G, Kollar M. Income in the United States: 2022. U.S. Census Bureau, Current Population Reports, P60-279. U.S. Government Publishing Office, Washington, DC, Sep 2023.

Lieberman DA. State of Obesity 2021: Better Policies for a Healthier America. Trust for America’s Health. 2021. Accessed May, 2024. https://www.tfah.org/report-details/state-of-obesity-2022.